Today we announced results from our nationwide Cancer Risk Survey: Breast Cancer Edition, which revealed that a majority (63%) of women do not know that there is an increased risk of breast cancer for women with dense breasts. The survey, now in its third year, focused on understanding the role of breast density and cancer risk among women ages 18+ in the U.S. Read the press release: https://brnw.ch/21wLlaT. #BreastDensity #BreastCancerRisk
Myriad Genetics
Biotechnology Research
Salt Lake City, Utah 83,732 followers
We're a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all.
About us
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs.
- Website
-
http://www.myriad.com/
External link for Myriad Genetics
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Salt Lake City, Utah
- Type
- Public Company
- Founded
- 1991
- Specialties
- Molecular Diagnostics, Personalized Medicine, Prognostic Medicine, Companion Diagnostics, Carrier Screen, Pharmacogenomics, Genetic Testing, Hereditary Cancer, Prostate Cancer, Breast Cancer, Prenatal Screen, Precision Medicine, Ovarian Cancer, Pancreatic Cancer, and Gender Testing
Locations
Employees at Myriad Genetics
Updates
-
Thank you Kathy Baker for sharing this impactful story about the CDKN2A gene mutation and its links to melanoma and pancreatic cancer risks. It's important that we continue to emphasize the importance of multi-gene testing to raise awareness and inform initiatives that help save lives through advanced genetic testing! #hereditarycancer #genetictesting #knowyourrisk
About a month ago, Martha Kaiser shared a post in support of Skin Cancer Awareness Month. Her post appeared in my feed because we "linked" up after My Faulty Gene memorialized her story and the story of two of her children and their CDKN2A (p16INK4a) gene mutation for our #FamilyGeneShare video project. While CDKN2A is not a gene we hear much about, most of us are familiar with other gene mutations which put individuals at risk of melanoma. Did you know that the CDKN2A (p16INK4A) mutation is not only associated with a HIGH RISK of melanoma, it is also associated with a HIGH RISK of pancreatic cancer? Although I'd spent hours with Martha and her family during their film shoot, I never knew a key fact about Martha's genetic testing. As she relates in her post, only BRCA testing was originally ordered for Martha--probably because of her mother's breast cancer history as well as her own melanoma history. Martha shared that after her test was ordered, Myriad Genetics offered extended panel testing rather than the limited test originally ordered by her gynecologist. Had the multi-gene panel testing not been ordered, Martha would not have known about her high risk of both melanoma and pancreatic cancer. I have shared numerous stories over the past several years about the benefits of multi-gene testing. And in our next series of videos we are currently scheduling for shooting this Fall, we will be including a couple of particularly compelling stories about the importance of multi-gene testing. While it is wonderful that providers other than genetic counselors and oncologists are ordering germline genetic testing--resulting in many mutations being identified--they can't be expected to be experts in knowing the best tests to order. So in addition to sharing Martha's family's important video to educate about a lesser-known gene mutation that can lead to deadly cancers, this post is also a reminder about the importance of utilizing genetic counselors in ordering tests. Referrals to genetic counselors are easy to make--and just might save a life! Here's the link to Martha, Erin and Nathan's video: https://lnkd.in/gg5-dEP8 #melanoma #pancreaticcancer #CDKN2A #melanomapancreaticcancersyndrome #hereditarycancer #knowyourrisk #familyhealthhistory #genetictesting #genetictestingsaveslives #geneticcounseling #geneticcounselor National Society of Genetic Counselors ConnectMyVariant.org CGA IGC
-
-
Today we announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). “Myriad and Personalis are each working to re-define the standard for MRD testing and increasing market access to better inform clinical decision making for the treatment and monitoring of oncology patients,” said Paul Diaz, President and CEO, Myriad Genetics. "We believe that our unique sets of capabilities and inclusive approach to using intellectual property for the benefit of patients will help drive broader MRD testing adoption, reimbursement, and greatly advance this opportunity for patients in this emerging and under-penetrated market. Myriad’s Precise MRD is a tumor-informed, genome-scale MRD test that is part of Precise Oncology Solutions, our expanding portfolio of comprehensive molecular diagnostic tools for oncology detection and treatment.” Read the press release below. #MRD #PatentEstates #Oncology
-
With the most inclusive groups and categories in healthcare advertising, the #AsterAwards are the nation’s most elite competition dedicated to recognizing the most talented healthcare marketing professionals for outstanding excellence in advertising, marketing and communications. Congratulations to our #WomensHealth teammates and partners at S50 and The Verdi Group for this three-time win!
Congratulations to the 2024 Aster Award Winners! - The Aster Awards
https://www.asterawards.com
-
Today we announced that the United States Patent and Trademark Office has issued a second foundational patent that will strengthen our ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. “The issuance of this second patent supporting our MRD assay development showcases another dimension of Myriad’s novel proprietary technology that we believe will help advance Myriad’s position as a precision medicine leader—both via its own Precise MRD offering and via potential licensing opportunities in the MRD space,” said Paul Diaz, president and CEO, Myriad Genetics. “We have developed our Precise® MRD assay by leveraging Myriad’s existing technology – laboratory systems, infrastructure, and intellectual property – and by building upon our FDA-approved MyChoice® CDx companion diagnostic and FirstGene platforms. We believe that our unique set of capabilities will enable us to profitably commercialize Precise MRD, advancing oncology care for patients in this emerging and under-penetrated market.” Read the press release below.
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
investor.myriad.com
-
We are excited to be at the #ISPD2024 conference in Boston, MA this week. Stop by booth #113 during exhibit hours to learn how we can support you and your patients through prenatal care. Be sure to also check out the two poster presentations we have today. Learn more about them below!
-
-
We're happy to announce that we've earned the 2024 Great Place To Work US Certification™ for the second year in a row! “At Myriad Genetics we are committed to fostering an open, collaborative and inclusive work environment where all teammates have an equal opportunity to grow and make a difference in our patients’ lives,” said Shereen Solaiman, chief people officer, Myriad Genetics. “The Great Place to Work Certification is a testament to the passion, talent and hard work our teammates bring to the Myriad workforce every day to fulfill our mission to advance health and well-being for all.” Read the press release below.
Myriad Genetics Earns 2024 Great Place To Work® Certification™
investor.myriad.com
-
Holly Pederson MD and Myriad’s Elisha Hughes sat down with Oncology Data Advisor’s Keira Smith to discuss recent research shared at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. They discuss the evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women. 🎧 Listen to the podcast: https://brnw.ch/21wKWYz
Developing a TNBC Polygenic Risk Score for Black Women: Holly Pederson, MD, and Elisha Hughes, PhD
soundcloud.com
-
Today we released the findings from our latest GeneSight® Mental Health Monitor, which revealed a significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season. “We hope that Americans will consider taking steps to improve their mental health as we get closer to this important election. The GeneSight test is one of the tools I’ve used to help my patients get back on the road to mental wellness,” said Thomas Valente, a psychiatrist from Leesburg, Florida. Read the press release below.
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
investor.myriad.com
-
Excited to see our own Lesley A. Manley included in this impressive list from Utah Business. This #Top100 recognizes exceptional legal knowledge, ethical standards and professional accomplishments that have made impacted their field. Congrats, Lesley! #legalElite #teamrecognition
In partnership with Kirton McConkie, Utah Business is proud to present this year’s Legal Elite. This award honors 100 leading lawyers in Utah who have made significant contributions in their respective legal fields. The following individuals are recognized for their exceptional legal knowledge, ethical standards and professional accomplishments. View all 100 honorees here: https://lnkd.in/gfMherBq 🖋: Melanie Paris Jones, Mekenna Malan & Beth Taylor
-
Affiliated pages
Similar pages
Browse jobs
Stock
MYGN
NASDAQ
20 minutes delay
$27.09
-0.3 (-1.095%)
- Open
- 27.11
- Low
- 26.963
- High
- 27.575
Data from Refinitiv
See more info on